Will Aurora Cannabis Stock Go to $0?
Or could it be a good contrarian buy?
The marijuana industry is expected to triple in the next five years -- and many investors are looking to profit. As states and entire countries decriminalize or legalize cannabis and/or its components, there are loads of opportunities for entrepreneurs and existing companies.
But as in any nascent industry, there are also loads of risks and bad actors. Whether you're a first-time investor or a seasoned veteran, it pays to understand all of the moving parts. This guide will get you up to speed quickly, and we'll share a couple of the marijuana companies that we watch closely.
|Green Thumb Industries (OTC:GTBIF)||Marijuana grower and retailer|
|Trulieve Cannabis (OTC:TCNNF)||Marijuana grower and retailer|
|Innovative Industrial Properties (NYSE:IIPR)||Ancillary provider|
|GrowGeneration (NASDAQ:GRWG)||Ancillary provider|
|Scotts Miracle-Gro (NYSE:SMG)||Ancillary provider|
|GW Pharmaceuticals (NASDAQ:GWPH)||Biotech|
Source: Yahoo Finance.
Green Thumb Industries (OTC:GTBIF) benefited from tremendous growth in its home state of Illinois throughout much of 2020. Illinois’ legal adult-use recreational marijuana market opened for business at the beginning of the year.
The company owns retail cannabis stores in 12 states across the U.S. and operates 13 manufacturing facilities. Green Thumb holds licenses for 96 retail cannabis locations but has opened only around half that many stores. That, along with the opportunity to expand into additional states, gives the company a significant growth runway.
Trulieve Cannabis (OTC:TCNNF) focuses primarily on the Florida medical cannabis market. And it dominates in the Sunshine State with roughly 50% of total sales.
The cannabis grower and retailer has been consistently profitable since 2017, an achievement few other marijuana companies can claim. Its sales and earnings continue to soar. Trulieve’s next big growth opportunity is in Massachusetts, where it expects to enter the state’s recreational marijuana market in 2021.
There’s one big downside to marijuana being illegal at the federal level in the U.S.: Cannabis companies can’t easily secure capital from banks or financial institutions. However, that creates a big opportunity for Innovative Industrial Properties (IIP) (NYSE:IIPR), which buys properties from U.S. medical cannabis operators and then leases the properties back to them. This gives the cannabis operator much-needed cash. And being in the landlord business gives IIP a steady revenue stream.
The COVID-19 pandemic disrupted IIP’s business a little, though, with three tenants receiving temporary rent deferrals due to coronavirus-related financial headwinds. But the company has still been able to deliver phenomenal growth during the pandemic. It’s highly profitable. Also, because the company is organized as a real estate investment trust (REIT), IIP must return at least 90% of its taxable income to shareholders in the form of dividends.
The booming U.S. cannabis industry has created a fast-growing market for supplies for hydroponics (growing plants without soil in liquid nutrient solutions) and organic gardening. GrowGeneration (NASDAQ:GRWG) is the largest specialty retail chain focused on this market.
While much of GrowGeneration’s business is catering to cannabis growers, the company also sells to other types of gardeners. GrowGeneration has seen a surge in customers who have jumped into organic gardening at home due to the COVID-19 pandemic.
Scotts Miracle-Gro (NYSE:SMG) is another company benefiting from the same trends that have boosted GrowGeneration’s sales. The company’s Hawthorne Gardening subsidiary ranks as a leading supplier of hydroponic gardening products to the cannabis industry.
Although Hawthorne is the primary growth driver for Scotts, the company still makes more than 70% of its revenue from sales of its consumer lawn and garden products. This business has also benefited from the COVID-19 pandemic.
In 2018, GW Pharmaceuticals' (NASDAQ:GWPH) Epidiolex became the first drug made from a cannabis plant to be approved by the U.S. Food and Drug Administration. Sales of Epidiolex routinely surpassed expectations in its initial approved indications, treating Dravet syndrome and Lennox-Gastaut syndrome, both of which are rare forms of childhood epilepsy. The cannabis-focused biotech saw new patient starts for Epidiolex slow a little with the COVID-19 pandemic, but it continued to deliver strong revenue growth.
In August, GW won FDA approval for Epidiolex in treating tuberous sclerosis complex (TSC), a rare disease whereby benign tumors grow in vital body organs. This opens up a significant new market to the company, as around 50,000 people in the U.S. and roughly 1 million people worldwide have the disease.
Let’s first cover some of the most important things you need to know to get started with investing in marijuana stocks:
1. There are three broad categories of marijuana stocks.
2. There are two primary cannabis markets.
3. Geography is tremendously important.
The COVID-19 pandemic has affected nearly every part of the global economy, including the cannabis industry. In many U.S. states, cannabis dispensaries have been designated as essential businesses. Cannabis sales boomed in some states during the first few months of the coronavirus outbreak as people sought ways to cope with the anxiety caused by lockdowns and the resulting economic chaos.
This trend boosted business for marijuana growers and retailers serving these states. It also helped ancillary providers supplying gardening and other products to these companies.
However, some cannabis companies were hit hard by the pandemic. For example, recreational cannabis retailers in tourist destinations such as Las Vegas saw their customer traffic dwindle as people avoided travel. Some of these companies started focusing on home delivery to generate revenue.
The top cannabis-focused biotech experienced challenges promoting its products to healthcare professionals. Many sales calls had to be conducted virtually, and new patient starts slipped as people delayed doctor visits.
We just went step-by-step through how to invest in cannabis, but just because there's a trendy new sector with lots of press and potential growth doesn't mean you need to put your hard-earned money in it. After all, if you buy broad index funds, you're covered no matter what sector of the stock market does well.
Think through the pros and cons as you read on: Should You Invest in Marijuana Stocks?
Or could it be a good contrarian buy?
The marijuana industry in general is doing well amid the pandemic. Does this beaten-down Canadian pot stock have any chance of rebounding?
U.S. legalization euphoria has investors chasing a number of terrible cannabis stocks.
While it's struggling now, this Canadian pot company could shine if management's plans pan out.
Curaleaf and GrowGeneration are running circles around Aurora.
Investors are all-in on this pot stock's plans to expand outside of Canada. Should you give its shares a try as well?
Cannabis has been reclassified as essentially a very minor threat.
The United States hasn't legalized weed yet -- but the United Nations just did, sort of.
The cannabis-focused REIT is rewarding its investors with larger cash dividends.
You're paying more for Canopy Growth than you think. Here's an alternative.